Bioventus Inc. (BVS) Stock

About Bioventus Inc.

Bioventus Inc. is led by CEO Robert E. Claypoole, employs 930 people, headquartered in US, publicly traded since 2021.

Bioventus Inc. (BVS) stock trades at $14.96 with a market capitalization of $1.02B. The stock is valued at a price-to-earnings (P/E) ratio of 16.85, price-to-book of 4.02, price-to-sales of 1.58. Over the past 52 weeks the stock has ranged between $6.37 and $15.89, and currently trades 5.9% below its 52-week high.

On profitability, Bioventus Inc. generates a return on equity (ROE) of 28.39%, above the typical market range of roughly 12-15%, return on capital employed of 11.87%, an operating margin of 10.64%, a net profit margin of 9.36%.

Bioventus Inc. by the numbers, 2014–2025

Compounded, revenue has grown 12.1% a year over five years, 3.5% over three, -0.9% over the last twelve months. Net profit was $23.0M in 2025.

The most recent net margin is 9.36%. On a trailing twelve-month basis to Jun '26, revenue is $582.0M and net profit $54.0M.

Borrowings rose from $171.0M to $311.0M, cash from operations was $74.0M in the latest year, positive in 9 of the last 12.

Return on equity has averaged -29.0% over five years, and was 12.5% in the most recent year.

The share price itself has compounded at -13.3% a year over five years, 39.3% over three, 29.1% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Bioventus Inc. (BVS) — frequently asked questions